What were the results of the PREVAIL and PROTECT AF trials regarding left atrial appendage closure?
The PREVAIL and PROTECT AF trials found that percutaneous closure of the left atrial appendage was non-inferior to warfarin therapy for prevention of stroke in patients with atrial fibrillation. The 5-year outcomes after left atrial appendage closure showed a lower risk of stroke or systemic embolism and a reduced risk of major bleeding with left atrial appendage closure compared to warfarin therapy. 